image: Octapharma USA presented research at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting evaluating the efficacy and safety of cutaquig® (Immune Globulin Subcutaneous ...

PARAMUS, N.J. (May 18, 2023) – An Octapharma-sponsored study published recently in The Journal of Clinical Immunology concludes that cutaquig ® (Immune Globulin Subcutaneous [Human]-hipp, 16.5% ...

According to FDA, the syringe pumps can cause "serious clinical consequences from lack of flow continuity resulting in delay of therapy, over-infusion or under-infusion," when operating at a rate of ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency ...

Longitudinal study of anti-myeloma treatment patterns in a U.S. commercial population before and after approval of bortezomib (BOR). The utility and prognostic value of positron emission tomography ...

Infusion centers are caught between two forces that won’t relent: patient volumes that keep climbing and clinician pipelines that can’t keep pace. For many organizations, the instinct is to hire more ...